keyword
MENU ▼
Read by QxMD icon Read
search

Direct antiviral agents

keyword
https://www.readbyqxmd.com/read/28199207/assessing-the-potential-function-of-adar1-in-virus-associated-sepsis
#1
Yugang Zhuang, Hu Peng, Yuanzhuo Chen, Shuqin Zhou, Yanqing Chen
Sepsis syndrome is a common and frequently fatal clinical condition. It is defined by the presence of both infection and an uncontrolled systemic inflammatory response. It represents a major, although largely unappreciated, healthcare problem worldwide. It is especially problematic in infants and toddlers who show markedly increased susceptibility to severe infections caused by various pathogens, including viruses. Viruses are important causative agents of sepsis. Host adenosine deaminase acting on RNA 1 (ADAR1) catalyzes adenosine to inosine (A-to-I) editing of RNA transcripts, thus changing viral RNAs and exerting antiviral and proviral effects...
March 1, 2017: Frontiers in Bioscience (Landmark Edition)
https://www.readbyqxmd.com/read/28195337/hepatitis-b-reactivation-in-hepatitis-b-and-c-coinfected-patients-treated-with-antiviral-agents-a-systematic-review-and-meta-analysis
#2
Guofeng Chen, Cheng Wang, Jing Chen, Dong Ji, Yudong Wang, Vanessa Wu, J Karlberg, George Lau
: There is an increased awareness of hepatitis B (HBV) reactivation in chronic hepatitis C (CHC) patients coinfected with HBV treated with pan-oral direct-acting antivirals (DAAs). We performed a systematic review and meta-analysis to compare the rate of HBV reactivation in CHC patients coinfected with overt HBV (hepatitis B surface antigen [HBsAg] positive) and occult HBV (HBsAg negative with positive HBV DNA) infection separately, treated with interferon (IFN)-based therapy to those with pan-oral DAAs...
February 13, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28193518/safety-and-efficacy-of-elbasvir-grazoprevir-in-patients-with-hepatitis-c-virus-infection-and-compensated-cirrhosis-an-integrated-analysis
#3
Ira M Jacobson, Eric Lawitz, Paul Y Kwo, Christophe Hézode, Cheng-Yuan Peng, Anita Y M Howe, Peggy Hwang, Janice Wahl, Michael Robertson, Eliav Barr, Barbara A Haber
BACKGROUND & AIMS: Persons with hepatitis C virus (HCV) infection are at risk of progressive liver disease, cirrhosis, and decompensation. We analyzed the effects of the direct-acting antiviral agents elbasvir and grazoprevir in patients with HCV infection and compensated cirrhosis, combining data from 6 clinical trials. METHODS: We performed an integrated analysis of 402 patients with HCV genotype 1, 4, or 6 infection and Child-Pugh A compensated cirrhosis enrolled in 6 clinical trials...
February 10, 2017: Gastroenterology
https://www.readbyqxmd.com/read/28192185/hepatic-decompensation-is-the-major-driver-of-death-in-hcv-infected-cirrhotic-patients-with-successfully-treated-early-hepatocellular-carcinoma
#4
Giuseppe Cabibbo, Salvatore Petta, Marco Barbara, Simona Attardo, Laura Bucci, Fabio Farinati, Edoardo G Giannini, Giulia Negrini, Francesca Ciccarese, Gian Lodovico Rapaccini, Maria Di Marco, Eugenio Caturelli, Marco Zoli, Franco Borzio, Rodolfo Sacco, Roberto Virdone, Fabio Andrea Marra Mega, Filomena Morisco, Luisa Benvegnù, Antonio Gasbarrini, Gianluca Svegliati-Baroni, Francesco Giuseppe Foschi, Andrea Olivani, Alberto Masotto, Gerardo Nardone, Antonio Colecchia, Marcello Persico, Antonio Craxì, Franco Trevisani, Calogero Cammà
BACKGROUND & AIMS: A major problem in assessing the long-term outcome of HCV-infected cirrhotic patients with successfully treated Barcelona Clinic Liver Cancer (BCLC) A hepatocellular carcinoma (HCC) arises from the lack of models accounting for early changes during follow-up. AIM: of study is to estimate the impact on 5-year overall survival (OS) of early (occurring within 12 months after complete radiological response) time-dependents events (HCC recurrence or hepatic decompensation) in a large cohort of successfully treated HCC patients with HCV cirrhosis...
February 9, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28191032/safety-of-new-daas-for-chronic-hcv-infection-in-a-real-life-experience-role-of-a-surveillance-network-based-on-clinician-and-hospital-pharmacist
#5
A Nappi, A Perrella, P Bellopede, A Lanza, A Izzi, M Spatarella, C Sbreglia
BACKGROUND: Direct Antiviral Agents (DAAs) for HCV therapy represents a step ahead in the cure of chronic hepatitis C. Notwithstanding the promising results in several clinical trials, few data are available on adverse effects in real life settings. METHODS: We have evaluated 170 patients with persistent infection and on those eligible to treatment we have followed up them through a network managed by clinician and hospital pharmacist. RESULTS: According to our data we have found that 41% (32 out of 78) of enrolled patients experienced adverse reactions, of these 40% were in those under 65 years while 60% was in patients older than 65 years, SVR was achieved in 88% of the patients (including drop-out)...
2017: Infectious Agents and Cancer
https://www.readbyqxmd.com/read/28187751/efficacy-safety-and-pharmacokinetics-of-simeprevir-and-tmc647055-ritonavir-with-or-without-ribavirin-and-jnj-56914845-in-hcv-genotype-1-infection
#6
RANDOMIZED CONTROLLED TRIAL
Stefan Bourgeois, Hans Van Vlierberghe, Christophe Moreno, Hans Orlent, Frederik Nevens, Keikawus Arastéh, Yves Horsmans, Jörn M Schattenberg, Peter Buggisch, Sven Francque, Leen Vijgen, Thomas N Kakuda, Eva Hoeben, Donghan Luo, An Vandebosch, Bert Jacquemyn, Pieter Van Remoortere, René Verloes
BACKGROUND: A Phase 2a, open-label study (NCT01724086) was conducted to assess the efficacy and safety of a once-daily, 2-direct-acting-antiviral-agent (2-DAA) combination of simeprevir + TMC647055/ritonavir ± ribavirin and of the 3-DAA combination of simeprevir + TMC647055/ritonavir + JNJ-56914845 in chronic hepatitis C virus genotype (GT)1-infected treatment-naïve and prior-relapse patients. METHODS: The study comprised four 12-week treatment panels: Panel 1 (n = 10; GT1a) and Panel 2-Arm 1 (n = 12; GT1b): simeprevir 75 mg once daily + TMC647055 450 mg once daily/ritonavir 30 mg once daily + ribavirin 1000-1200 mg/day; Panel 2-Arm 2 (n = 9; GT1b): simeprevir 75 mg + TMC647055 450 mg/ritonavir 30 mg without ribavirin; Panel 3: simeprevir 75 mg + TMC647055 600 mg/ritonavir 50 mg with (Arm 1: GT1a; n = 7) or without (Arm 2: GT1b; n = 8) ribavirin; Panel 4: simeprevir 75 mg + TMC647055 450 mg/ritonavir 30 mg + JNJ-56914845 30 mg once daily (Arm 1: n = 22; GT1a/GT1b) or 60 mg once daily (Arm 2: n = 22; GT1a/GT1b)...
February 10, 2017: BMC Gastroenterology
https://www.readbyqxmd.com/read/28185946/decreased-tacrolimus-plasma-concentrations-during-hcv-therapy-a-drug-drug-interaction-or-is-there-an-alternative-explanation
#7
E J Smolders, S Pape, C T M M de Kanter, A P van den Berg, J P H Drenth, D M Burger
Chronic hepatitis C virus (HCV) infection can cause severe liver cirrhosis, for which liver transplantation is the only therapy. To prevent organ rejection, transplanted patients are treated with immunosuppressive agents. We describe two transplanted patients treated with tacrolimus who were simultaneously treated with direct-acting antivirals (DAAs) for their chronic HCV infection. No pharmacokinetic drug-drug interactions (DDIs) were expected between tacrolimus and the selected DAAs. However, in both patients, tacrolimus plasma concentrations decreased during HCV treatment...
February 6, 2017: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/28183063/real-life-experience-with-direct-acting-antivirals-agents-against-hepatitis-c-infection-in-elderly-patients
#8
Iria Rodríguez-Osorio, Purificación Cid, Luis Morano, Ángeles Castro, Marta Suárez, Manuel Delgado, Luis Margusino, Héctor Meijide, Berta Pernas, Andrés Tabernilla, José D Pedreira, Álvaro Mena, Eva Poveda
BACKGROUND: New direct-acting antivirals agents (DAAs) are very safe and well tolerated. OBJECTIVES: The purpose of this study is to analyse the efficacy and safety of DAAs in elderly patients, who have co-morbidities and are on chronic medications. STUDY DESIGN: All HCV-infected patients over 65 years old in clinical follow-up at two Hospitals in Spain who initiated anti-HCV therapy were included (August 2012-October 2015). RESULTS: A total of 120 HCV mono-infected patients were recorded...
January 18, 2017: Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology
https://www.readbyqxmd.com/read/28182613/news-on-viral-hepatitis-in-hiv-update-from-the-2016-gehep-conference
#9
Eva Poveda, Massimo Puoti, Miguel García-Deltoro, Juan A Pineda, Francisco Téllez, Rafael Granados, Luis Morano, Federico García
The II Conference of the Group for the Study of Viral Hepatitis (GEHEP) (29 September-1 October, Spain) updated epidemiological, diagnostic and treatment aspects on viral hepatitis. The conference was mostly focused on the latest news related to HCV infection, including the successes achieved since the implementation of direct-acting antiviral agents for HCV therapy, but also in the new, future challenges for a real HCV eradication. The scenario for chronic HCV infection has dramatically changed in the last two years and most patients have been cured after 12 weeks of therapy with minimal side effects...
January 2017: AIDS Reviews
https://www.readbyqxmd.com/read/28170123/martinello-et%C3%A2-al-hcv-reinfection-incidence-among-individuals-treated-for-recent-infection
#10
Patrick Ingiliz
The development of all-oral direct-acting antiviral agents (DAA) has changed the management of patients infected with the hepatitis C virus (HCV). As these new treatments are safe and highly effective, most affected patients may have a chance for HCV cure, at least in those parts of the world where the costly drugs available. In industrialized countries, HCV infection has a comparatively low prevalence in the general population(1) . A higher prevalence and new infections are mainly seen in two specific subgroups: people who inject drugs (PWID) and HIV-positive men who have sex with men (MSM)...
February 7, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28170112/treatment-of-hepatitis-c-virus-infection-in-patients-with-cirrhosis-and-predictive-value-of-meld-analysis-of-data-from-the-hepa-c-registry
#11
Carlos Fernández Carrillo, Sabela Lens, Elba Llop, Juan Manuel Pascasio, Javier Crespo, Juan Arenas, Inmaculada Fernández, Carme Baliellas, José Antonio Carrión, Manuel de la Mata, Maria Buti, Lluís Castells, Agustín Albillos, Manuel Romero, Juan Turnes, Clara Pons, José María Moreno-Planas, José Javier Moreno-Palomares, Conrado Fernández-Rodriguez, Javier García-Samaniego, Martín Prieto, Miguel Fernández Bermejo, Javier Salmerón, Ester Badia, Magdalena Salcedo, José Ignacio Herrero, Rafael Granados, Michel Blé, Zoe Mariño, José Luis Calleja
Direct-acting antiviral agents (DAAs) are highly effective and well tolerated in patients with chronic hepatitis C virus (HCV) infection, including those with compensated cirrhosis. However, fewer data are available in patients with more advanced liver disease. Our retrospective, non-interventional, national, multi-center study in patients from the Spanish Hepa-C registry investigated the effectiveness and safety of interferon-free DAA regimens in patients with advanced liver disease, including those with decompensated cirrhosis, in routine practice (all currently approved regimens were registered)...
February 7, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28166520/universal-sustained-viral-response-to-the-combination-of-ombitasvir-paritaprevir-ritonavir-and-dasabuvir-with-without-ribavirin-in-patients-on-hemodialysis-infected-with-hepatitis-c-virus-genotypes-1-and-4
#12
Soraya Abad, Almudena Vega, Eduardo Hernández, Evangelina Mérida, Patricia de Sequera, Marta Albalate, Nicolás Macías, Monica Milla, Juan M López-Gómez
BACKGROUND: Hepatitis C virus (HCV) infection is highly prevalent among patients on hemodialysis (HD) and is associated with poor prognosis. Treatment with interferon and ribavirin is poorly tolerated, and few data are available on the impact of new direct-acting antivirals (DAAs). This study was intended to analyze the efficacy and safety of treatment with a combination of ombitasvir/paritaprevir/ritonavir and dasabuvir with/without ribavirin in HCV-infected patients on HD from 3 hospitals...
January 7, 2017: American Journal of Nephrology
https://www.readbyqxmd.com/read/28165585/hepatitis-c-virus-infection-in-maintenance-hemodialysis-patients-recommendations-for-diagnostics-and-treatment
#13
Pavlina Dzekova-Vidimliski, Aleksandar Sikole
Hepatitis C virus (HCV) infection is highly prevalent among patients treated with maintenance hemodialysis and is an important cause of morbidity and mortality. It is necessary to determine the HCV genotype and the viral load to monitor the clinical and laboratory features and to establish an optimal antiviral treatment strategy. Antiviral treatments are presented with a standard interferon-based regimen and new direct-acting antiviral agents. The advent of direct-acting antivirals has improved the efficacy and safety of HCV treatment for most patients, even in difficult-to-treat populations such as patients on hemodialysis...
February 1, 2017: International Journal of Artificial Organs
https://www.readbyqxmd.com/read/28159934/risk-of-hepatitis-c-virus-related-hepatocellular-carcinoma-between-subjects-with-spontaneous-and-treatment-induced-viral-clearance
#14
Chung-Feng Huang, Ming-Lun Yeh, Ching-I Huang, Yu-Ju Lin, Pei-Chien Tsai, Zu-Yau Lin, Soa-Yu Chan, Shinn-Cherng Chen, Hwai-I Yang, Jee-Fu Huang, Sheng-Nan Lu, Chia-Yen Dai, Chin-Lan Jen, Yong Yuan, Gilbert L'Italien, Li-Yu Wang, Mei-Hsuan Lee, Ming-Lung Yu, Wan-Long Chuang, Chien-Jen Chen
BACKGROUND/AIMS: Both spontaneous hepatitis C virus (HCV) clearance and the achievement of sustained virological response (SVR) by anti-viral therapy greatly reduce the incidence of hepatocellular carcinoma (HCC). The current study aimed to compare the risk of HCC between the two patient groupsMethods: A total of 313 subjects with spontaneous HCV clearance (SC) and 564 age- and sex-matched patients in the treatment-induced SVR group were enrolled for analysis. RESULTS: Nineteen (2...
February 1, 2017: Oncotarget
https://www.readbyqxmd.com/read/28149651/hepatitis-c-virus-and-cardiovascular-a-review
#15
REVIEW
Salvatore Petta
Chronic hepatitis C virus (HCV) infection is a systemic disease that leads to increased risks of cirrhosis and its complications, as well as extrahepatic disturbances, including immune-related disorders and metabolic alterations such as insulin resistance and steatosis. Recent accumulating evidence suggests that HCV infection can increase cardiovascular risk, and that viral eradication can improve cardiovascular outcomes in the clinical setting. These data are strengthened by evidence identifying potential mechanisms (in)directly linking HCV infection to vascular damage...
March 2017: Journal of Advanced Research
https://www.readbyqxmd.com/read/28149647/hepatitis-c-and-kidney-disease-a-narrative-review
#16
REVIEW
Rashad S Barsoum, Emad A William, Soha S Khalil
Hepatitis-C (HCV) infection can induce kidney injury, mostly due to formation of immune-complexes and cryoglobulins, and possibly to a direct cytopathic effect. It may cause acute kidney injury (AKI) as a part of systemic vasculitis, and augments the risk of AKI due to other etiologies. It is responsible for mesangiocapillary or membranous glomerulonephritis, and accelerates the progression of chronic kidney disease due to other causes. HCV infection increases cardiovascular and liver-related mortality in patients on regular dialysis...
March 2017: Journal of Advanced Research
https://www.readbyqxmd.com/read/28149646/vasculitic-syndromes-in-hepatitis-c-virus-a-review
#17
REVIEW
Gaafar Ragab, Mohamed A Hussein
Vasculitis is a remarkable presentation of the extrahepatic manifestations of HCV. According to the presence or absence of cryoglobulins it is subdivided into two main types: cryoglobulinemic vasculitis and non cryoglobulinemic vasculitis based on the attribution of vasculitis to serum cryoglobulins as a pathogenic factor. The attribution of cryoglobulinemia to HCV represents a success story in the history of immunology, microbiology, and clinical medicine. HCV can bind to and invade lymphocytes, consequently triggering an immune response through different mechanisms...
March 2017: Journal of Advanced Research
https://www.readbyqxmd.com/read/28149332/the-immunomodulatory-anticancer-agent-rrx-001-induces-an-interferon-response-through-epigenetic-induction-of-viral-mimicry
#18
Hongjuan Zhao, Shoucheng Ning, Rosalie Nolley, Jan Scicinski, Bryan Oronsky, Susan J Knox, Donna M Peehl
BACKGROUND: RRx-001, a dinitroazetidine derivative, is a novel anticancer agent currently in phase II clinical trials. It mediates immunomodulatory effects either directly through polarization of tumor associated macrophages or indirectly through vascular normalization and increased T-lymphocyte infiltration. With multiple additional mechanisms of action including upregulation of oxidative stress, depletion of GSH and NADPH, anti-angiogenesis and epigenetic modulation, RRx-001 is being studied as a radio- and chemo-sensitizer to resensitize tumors to prior therapy and to prime tumors to respond to radiation, chemotherapy and immunotherapy in combination therapy studies...
2017: Clinical Epigenetics
https://www.readbyqxmd.com/read/28138248/rapid-virological-response-of-telaprevir-and-boceprevir-in-a-brazilian-cohort-of-hcv-genotype-1-patients-a-multicenter-longitudinal-study
#19
Helena Hl Borba, Astrid Wiens, Laiza M Steimbach, Fernanda S Tonin, Maria LA Pedroso, Cláudia Ap Ivantes, Fernando Fernandez-Llimos, Roberto Pontarolo
BACKGROUND: Chronic hepatitis C is a major public health issue, but there is a gap in the literature regarding the effectiveness and safety of direct-acting antiviral agents in the Brazilian population. The main aim of this study was to describe the effectiveness of boceprevir and telaprevir in patients treated at public health care institutions in Brazil. MATERIALS AND METHODS: A prospective longitudinal and multicenter study was conducted in five centers in the State of Paraná between September 2014 and June 2016...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28114144/hepatitis-c-treatment-in-chronic-kidney-disease-patients-the-kidney-disease-improving-global-outcomes-perspective
#20
Michel Jadoul, Paul Martin
BACKGROUND: Hepatitis C virus (HCV) infection is a very common infection found among hemodialysis (HD) and kidney transplant patients. It is associated with substantial morbidity and mortality. Direct-acting antiviral agents (DAAs) have much better efficacy (sustained viral response (SVR)) and tolerance than interferon-based regimens. Very recent studies extend this breakthrough finding to chronic kidney disease (CKD) populations. SUMMARY: CKD patients with an estimated glomerular filtration rate (eGFR) >30 ml/min/1...
January 24, 2017: Blood Purification
keyword
keyword
12534
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"